← back to search

Andrea R. Hagemann

Alvin J. Siteman Cancer Center · US
🔎 Find collaborators in Reproductive Medicine · Immunology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Reproductive Medicine · Immunology
Research interest
Research interests include Ovarian cancer diagnosis and treatment, Phagocytosis and Immune Regulation, Endometrial and Cervical Cancer Treatments, and Pancreatic and Hepatic Oncology Research.
h-index
29
citations
4,162
works
431
NIH funding
primary concept
Medicine
email

Recent publications

Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer
Cancers 2025cited by 12position: firstdoi
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
Gynecologic Oncology 2025cited by 10position: middledoi
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination–proficient ovarian cancer
Journal of Clinical Investigation 2025cited by 6position: middledoi
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network 2024cited by 85position: middledoi
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
Journal of the National Comprehensive Cancer Network 2023cited by 275position: middledoi
Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival
Communications Biology 2023cited by 31position: middledoi
Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins
Molecular Cancer Research 2023cited by 22position: middledoi
GAS6 inhibition induces platinum sensitivity through increased replication stress in ovarian cancer
Gynecologic Oncology 2021cited by 0position: middledoi
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
Journal of Clinical Oncology 2020cited by 346position: middledoi
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
New England Journal of Medicine 2019cited by 922position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David G. Mutch · Cancer Research Center4 papers (2021–2025)Ian S. Hagemann · Washington University in St. Louis4 papers (2021–2025)Premal H. Thaker · Barnes-Jewish Hospital4 papers (2021–2025) · 3 papers (2021–2023)Carolyn K. McCourt · Gynecologic Oncology Group3 papers (2021–2023)Katherine C. Fuh · UCSF Helen Diller Family Comprehensive Cancer Center3 papers (2021–2023)Matthew A. Powell · Jewish Hospital3 papers (2021–2023)Dineo Khabele · University of Kansas2 papers (2023–2023) · 2 papers (2021–2023) · 2 papers (2021–2023)Gregory D. Longmore · Washington University in St. Louis2 papers (2023–2023)Lindsay M. Kuroki · Twitter (United States)2 papers (2021–2023)Elizabeth Stock · Barrick Gold (Canada)1 papers (2023–2023)Heather A. Lankes · NRG Oncology1 papers (2020–2020)Robert W. Holloway · AdventHealth Orlando1 papers (2025–2025)Molly M. Greenwade · University of Oklahoma Health Sciences Center1 papers (2023–2023)Tiandao Li · University of Iowa1 papers (2023–2023) · 1 papers (2021–2021)Emilee N. Kotnik · University of Michigan–Ann Arbor1 papers (2023–2023)Peinan Zhao · Shanxi Medical University1 papers (2023–2023)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Reproductive Medicine · Immunology →